AM3 (Inmunoferón ®) as an adjuvant to hepatitis B vaccination in hemodialysis patients

Kidney International

Volumn 61, Issue 5, 2002, Pages 1845-1852

  Pérez García, Rafael ^a,b,c,d,e   Pérez García, Alfonso ^a,b,c,d,e   Verbeelen, Dierik ^a,b,c,d,e   Bernstein, Erica D ^a,b,c,d,e   Villarrubia, Vicente G ^a,b,c,d,e   Álvarez Mon, Melchor ^a,b,c,d,e  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^c UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^d HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^e Industrial Farmacéutica Cantabria   (Spain)

Author keywords

Adjuvant therapy; Dialysis infection; Immunity; Seroconversion; Vaccine

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; IMMUNOFERON; PLACEBO; RECOMBINANT DNA;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERANCE; FEMALE; HEMODIALYSIS; HEPATITIS B; HUMAN; IMMUNITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SEROLOGY; TIME; VACCINATION;

EID: 0036239855     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2002.00335.x     Document Type: Article

References (57)

1. T cells and B cells in chronic renal failure
2. Mortality in dialysis patients: Analysis of the causes of death
3. National surveillance of dialysis associated diseases in the United States-1994
4. Protective effect of hepatitis B vaccine in chronic hemodialysis patients
5. Hepatitis B vaccine in hemodialysis patients with hepatitis C viral infection
6. Intradermal versus intramuscular hepatitis B re-vaccination in non-responsive chronic dialysis patients: A prospective randomized study with cost-effectiveness evaluation
7. Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients
8. Efficacy of different hepatitis B vaccination strategies in patients receiving hemodialysis
9. Responsiveness to hepatitis B vaccine in immuno-compromised patients by doubling the dose scheduling
10. The use of vaccines in renal failure
11. Successful vaccination with intradermal hepatitis B vaccine in hemodialysis patients previously nonresponsive to intramuscular hepatitis B vaccine
12. A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients
13. Immune response after vaccination with recombinant hepatitis surface antigen in maintenance hemodialysis patients and healthy controls
14. A successful two-step integrated protocol of anti-HBV vaccination in chronic uremia
15. Hepatitis B vaccine: Randomized trial of immunogenicity in hemodialysis patients
16. Increasing serum creatinine and age reduce the response to hepatitis B vaccine in renal failure patients
17. Non-responsiveness to hepatitis B vaccination in hemodialysis patients: Association with impaired TCR/CD3 antigen receptor expression regulating co-stimulatory processes in antigen presentation and recognition
18. Immunologic function and survival in hemodialysis patients
19. Characteristic cytokine products of Th 1 and Th2 cells in hemodialysis patients
20. Hemodialysis-related lymphomononuclear release of interleukin-12 in patients with end-stage renal disease
21. T-cell activation follows Th1 rather than Th2 pattern in hemodialysis patients
22. Low-dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination
23. Randomized placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine
24. Effects of interleukin-2 on hepatitis B vaccination in uraemic patients
25. Effects of recombinant interleukin-2 and revaccination for hepatitis B in previously vaccinated, non-responder, chronic uraemic patients
26. Granulocyte-macrophage colony-stimulating factor given as an adjuvant to persons not responding to hepatitis B vaccine
27. Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination of healthy adults
28. Recombinant γ-interferon as adjuvant to hepatitis B vaccine in hemodialysis patients
29. Evaluation of treatments for the vaccination against hepatitis B + thymopentine
30. Brief treatment with thymopentin as adjuvant in vaccination for hepatitis B: Controlled study in patients on periodic hemodialysis
31. Influence of thymopentin on antibody response, and monocyte and T cell function in hemodialysis patients who fail to respond to hepatitis B vaccination
32. Controlled trial of thymopentin in hemodialysis patients who fail to respond to hepatitis B vaccination
33. Enhancement of lymphocyte proliferation, interleukin-2 production and NK activity by inmunoferon (AM-3), a fungal immunomodulator: Variations in normal and immunosuppressed mice
34. Immunoferon (AM3) enhances the activities of early-type interferon inducers and natural killer cells
35. The immunosenescent phenotype in mice and humans can be defined by alterations in the natural immunity reversal by immunomodulation with oral AM3
36. New vaccines and the immune response. II. The environment of the antigen presentation. Adjuvants as inducers of cell-mediated immunity
37. Hepatitis B virus and the inflammatory/immunologic response (II): A new opportunity for the treatment of chronic hepatitis B and a suggestion for the treatment of other persistent viral diseases
38. Therapeutic impact of AM3 (biological response modifier) on prevention of recurrent acute infections of the respiratory tract. Analysis of 683 persons at high risk
39. Immunologic clinical evaluation of a biological response modifier, AM3, in the treatment of childhood infectious respiratory pathology
40. AM3 (a biological response modifier) in the treatment of recurrent aphthous stomatitis. Clinical evaluation and preliminary studies on NK (CD16) cells and their pathogenic role in the syndrome
41. Therapeutic response of chronic active hepatitis B (CAHB) to a new immunomodulator: AM 3. Immunohematological effects
42. Preliminary report on the efficacy of a biological response modifier (AM3) in the treatment of chronic hepatitis B
43. AM3, an adjuvant to hepatitis B revaccination in non-responder healthy persons
44. Antibody level after hepatitis B vaccination in hemodialysis patients: Influence of hepatitis C virus infection
45. Are booster immunisations needed for lifelong hepatitis B immunity?
46. Hepatitis B vaccination in high-risk infants: 10-year follow-up
47. Early immunisation with hepatitis B vaccine: A five year study
48. Correlation between in vivo humoral and in vitro cellular immune responses following immunization with hepatitis B surface antigen (HBsAg) vaccines
49. Deficient T-cell responses in non-responders to hepatitis B vaccination: Absence of TH1 cytokine production
50. Lifelong protection against hepatitis B: The role of vaccine immunogenicity in immune memory
51. Four year experience with a recombinant hepatitis B vaccine
52. Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients
53. Hepatitis B vaccine, hepatitis C virus infection, and hemodialysis
54. Hepatitis C virus infection decreases the effective antibody response to hepatitis B vaccine in hemodialysis patients
55. The effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on hepatitis B vaccination in hemodialysis patients
56. The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic hemodialysis patients who have failed primary vaccination